Capital Fund Management S.A. Increases Stake in Medpace Holdings, Inc. $MEDP

Capital Fund Management S.A. raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 129.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 32,412 shares of the company’s stock after purchasing an additional 18,287 shares during the quarter. Capital Fund Management S.A. owned 0.12% of Medpace worth $16,665,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Wasatch Advisors LP increased its stake in shares of Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the period. AQR Capital Management LLC grew its holdings in Medpace by 15.1% in the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after acquiring an additional 81,637 shares during the last quarter. Baillie Gifford & Co. grew its holdings in Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after acquiring an additional 62,503 shares during the last quarter. Epoch Investment Partners Inc. increased its position in shares of Medpace by 11.4% in the second quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock valued at $139,740,000 after acquiring an additional 45,435 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Medpace by 79.3% in the second quarter. JPMorgan Chase & Co. now owns 265,270 shares of the company’s stock valued at $83,258,000 after acquiring an additional 117,301 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 2.3%

Medpace stock opened at $477.72 on Thursday. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $628.92. The company has a market capitalization of $13.56 billion, a price-to-earnings ratio of 31.22, a price-to-earnings-growth ratio of 2.24 and a beta of 1.44. The business’s fifty day simple moving average is $528.39 and its two-hundred day simple moving average is $539.24.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company’s revenue was up 32.0% on a year-over-year basis. During the same period last year, the company earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a research note on Friday, February 13th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Finally, Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Five equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.